Prometic Receives Priority Review Status From Health Canada

Prometic Life Sciences (TSX:PLI; OTCQX:PFSCF) announced it received a priority review status from Health Canada regarding its new drug submission for its plasminogen replacement therapy, Ryplazim, for the treatment of patients with plasminogen deficiency.
As quoted in the press release:

“We are pleased to have secured another priority review status for Ryplazim”, said Pierre Laurin, President and Chief Executive Officer of Prometic. “We see this as further validation by a regulatory authority of the potential value of this life-changing drug in the treatment of plasminogen deficiency. We look forward to continuing to work with Health Canada to bring this innovative therapy to patients suffering from plasminogen deficiency”.
Priority Review status assigns eligible submissions a shortened review target of 180 days, in comparison to 300 days for non-priority. Health Canada believes it is in the best interests of Canadians to review potentially life-saving drugs as early as possible.

Click here to read the full press release.

Source: www.newswire.ca